the joseph and wolf lebovic cancer genomics and immunity fellowship program aims to support projects that will uncover the diverse interactions between tumour and immune cells, for the development of new therapeutic strategies. the program aims to harness the power of genomic analytic tools with that of diverse animal and cellular experimental systems, through collaborative work between the ontario institute for cancer research (oicr) and the institute for medical research israel-canada (imric) scientists. imric an institute of the hebrew university.

scope

• the program will provide support for trainees – 世界杯2022赛程表淘汰赛 /postdoctoral fellows – working on joint projects between imric and ontario-based scientists addressing the interactions between cancer and immune cells;
• two projects will be selected to receive support over a two-year period;
• each collaborative project will support two trainees, one from each institution; and
• each project will be funded at $80,000 cad per year divided equally between the two institutions ($40,000 cad per institution per year).

partnership engage grants are expected to respond to the objectives of the insight program and the connection program. please note that partnership engage grants cannot respond exclusively to the objectives of the connection program.

these grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector. the small-scale, stakeholder-driven partnerships supported through partnership engage grants are meant to respond to immediate needs and time constraints facing organizations in non-academic sectors. in addressing an organization-specific need, challenge and/or opportunity, these partnerships let non-academic organizations and postsecondary researchers access each other’s unique knowledge, expertise and capabilities on topics of mutual interest.

sshrc welcomes applications involving indigenous research, as well as those involving research-creation.

the three canadian federal research funding agencies and uk research and innovation(ukri) are pleased to announce their intention to launch the canada-uk artificial intelligence initiative. 

the canadian agencies include the canadian institutes of health research (cihr); the natural sciences and engineering research council (nserc); and the social sciences and humanities research council (sshrc). the four uk research councils involved in this ukri initiative are the arts and humanities research council (ahrc); the economic and social research council (esrc); the engineering and physical sciences research council (epsrc); and the medical research council (mrc). esrc is coordinating this initiative. 

the rapid development and ever-growing global investment in artificial intelligence (ai) illustrate the undeniable impact that these technologies are having, and will have, on our economies, health and societies. given the expertise of researchers in canada and the united kingdom, the canadian agencies and ukri are jointly supporting the development of a collaboration in ai among stakeholders in canada and the uk aimed at building competitive and resilient economies and maximizing the social and health benefits. the aim is to build competitive and resilient economies and maximize the social and health benefits.

this is a unique collaboration which will require each project to include a principal investigator (pi) based in canada and a pi based in the uk who will share equally leadership and project management responsibilities. the canadian and uk applicants will develop a common research plan and jointly prepare the full proposal. proposals will be required to demonstrate a significant degree of, or novel approach to, interdisciplinarity, with research that cuts across at least two of the following research domains: social sciences and humanities; health and biomedical sciences; and natural sciences and engineering (including computational and/or mathematical sciences).  

in addition to promoting interdisciplinary ai, this call will support the development of responsible ai while establishing new partnerships and enhancing infrastructure and training between researchers in canada and the uk. the outputs and outcomes of the research should allow for uptake by relevant stakeholders where possible.

the fy19 defense appropriation provides $20 million (m) to the department of defense joint program committee 8/clinical and rehabilitative medicine research program (jpc-8/crmrp) to support the development of regenerative medicine solutions and technical capabilities that repair, reconstruct, or regenerate tissue lost or damage due to traumatic injury through collaborative partnerships and synergistic projects that inform and build on each other.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the jpc-8/crmrp is offering the regenerative medicine focused research award (rmfra) as its next iteration of the armed forces institute of regenerative medicine (afirm), afirm iii, in fy19 to continue its effort to support the development of regenerative medicine solutions.  the fy19 jpc-8/crmrp program announcement and general application instructions for the rmrfa mechanism are posted on the grants.gov website. 

focus areas and areas of encouragement

all projects submitted under the fy19 jpc-8/crmrp rmfra will be required to address one or both of the following focus areas:

• ·         peripheral nerve regeneration
• ·         skeletal muscle regeneration

efforts to regenerate peripheral nerve should focus on restoring maximal function; the goal should be accelerating functional recovery and/or reducing the need for autograft; efforts should not simply address metrics of nerve regrowth or conduits to cross nerve gaps.  similarly efforts to regenerate skeletal muscle should extend beyond restoration of muscle bulk or structure and address restoration of maximal muscle function.  the fy19 jpc-8/crmrp rmfra areas of encouragement include:

• ·         immediate reconnection of severed peripheral nerves (e.g., preventing wallerian degeneration)
• ·         regeneration of composite muscle and nerve injuries leading to improved function
• ·         regenerative therapies for volumetric muscle loss
• ·         preservation of denervated end organs
• ·         maintenance of the motor end plate or regeneration of the neuromuscular junction
• ·         improving the rate of peripheral nerve regeneration

https://cdmrp.army.mil/funding/jpc8

regenerative medicine focused research award (rmfra) – preproposal due august 7, 2019

independent investigators at all academic levels (or equivalent)

• ·        preproposal is required; full application submission is by invitation only.
• ·        accommodates either single principal investigator (pi) or multiple pi submissions.  all research teams should include highly qualified investigators. partnerships should include multidisciplinary investigators that bring resources and expertise that combine to create a robust, synergistic collaboration.
• ·        supports the development of regenerative medicine technical capabilities and solutions through collaborative partnerships and synergistic projects (multiple pi submissions) or through comprehensive projects (single pi submissions) to accelerate regenerative medicine solutions and technical capabilities that repair, reconstruct, or regenerate tissue lost or damaged due to traumatic injury
• ·        multi-institutional collaborations between/among academia, industry, and department of defense and/or department of veterans affairs facilities are highly encouraged.
• ·        research projects should be either advanced preclinical research or early stage clinical trials (phase 0, i, or iia)
• ·        applications must address one or both of the fy19 joint program committee 8/crmrp rmfra focus areas
• ·      maximum funding of $10 million (m) for total costs (direct plus indirect costs).
• ·      submissions may range in size and scope as appropriate for the work proposed, and will be equally considered.  submissions with a total of less than the maximum  of $10m are encouraged
• ·      maximum period of performance is 5 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcement and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the jpc-8/crmrp, please visit the crmrp website (https://crmrp.amedd.army.mil).

point of contact:

cdmrp help desk 
301-682-5507
help@ebrap.org

the fy19 defense appropriation provides $20 million (m) to the department of defense kidney cancer research program (kcrp) to support research of exceptional scientific merit in the area of kidney cancer.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc).

fy19 kcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

https://cdmrp.army.mil/funding/kcrp

academy of kidney cancer investigators - dean award – letter of intent due september 17, 2019

dean must be an established kidney cancer researcher.

• ·       supports visionary individuals who are established kidney cancer researchers with a strong record of mentoring and commitment to leadership.
• ·       academy dean will oversee an interactive virtual academy of early-career investigators and their designated mentors, facilitate regular interactive communication among all academy members, and assess the research progress and career progression of the early-career investigators.
  • ·      maximum funding of $625,000 for direct costs (plus indirect costs).
• ·       maximum period of performance 5 years.
• ·       indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

academy of kidney cancer investigators - early career investigator award – letter of intent due september 17, 2019

must be within 3 years of his/her last postdoctoral research position (ph.d.) or clinical fellowship (m.d.), or equivalent as of full application submission deadline.

letter attesting to eligibility required.

• ·       supports addition of new early-career investigators to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.
• ·       early-career investigators whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
• ·       a designated mentor who is an experienced kidney cancer researcher with kidney cancer funding is required.
• ·       the designated mentor not required to be at the same institution as the early-career investigator.
• ·       preliminary data required.
• ·       clinical trials are not allowed.
  • ·      maximum funding of $725,000 for direct costs (plus indirect costs).
• ·       maximum period of performance 4 years.
• ·       indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

clinical consortia award – letter of intent due september 17, 2019

independent investigators at or above the level of assistant professor (or equivalent)

• ·       supports development of a consortium that will facilitate rapid execution of collaborative clinical trials that will bring to market high-impact, novel therapeutics that will ultimately and significantly decrease the impact of kidney cancer.
• ·       funds may not be used for research or development of clinical protocols.
• ·       trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer encouraged.
• ·       one coordinating center and three clinical trial sites will be selected and be jointly responsible for proposing, selecting, and conducting trials.
• ·       sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer
• ·       consortium expected to achieve financial self-sufficiency, such that operations can continue after the award ends.
• ·       the consortium is expected to achieve financial self-sufficiency, such that operations can continue after the award period ends.

coordinating center:

• ·       maximum funding of $3m for direct costs (plus indirect costs).
  • ·      maximum period of performance is 3 years.
  • ·      indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

clinical trial sites:

• ·      maximum funding of $600,000 for direct costs (plus indirect costs).
• ·       maximum period of performance is 3 years.
• ·       indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrmc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the kcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org

the fy19 defense appropriation provides $10 million (m) to the department of defense orthotics and prosthetics outcomes research program (oporp) to support research that evaluates the comparative effectiveness of orthotic and prosthetic clinical interventions using patient-centric outcomes for service members and veterans who have undergone limb amputation.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc).

fy19 oporp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

oporp awards are focused on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology.  the intent of the awards is to generate clinically useful evidence that will enhance and optimize patient outcomes.

focus areas:  the oporp will only consider applications that specifically address the critical needs of the orthotics and prosthetics outcomes research community in one or more of the fy19 focus areas.  the oporp will solicit research applications that address at least one of the following fy19 focus areas:

• orthotic or prosthetic device form:  understand patient outcomes through the analysis and characterization of variables related to the form of currently available clinical options such as device size, shape, material, and/or configurations.
• orthotic or prosthetic device fit:  understand patient outcomes related to human-device interface and component connection through the analysis of variables in currently available clinical options that facilitate fit-related metrics such as comfort and/or usability.
• orthotic or prosthetic device function:  understand patient outcomes through the analysis of variables related to currently available device function such as device control, sensors, and passive or active response with respect to activities of daily living and other real-world activities.

https://cdmrp.army.mil/funding/oporp

clinical research award – letter of intent due july 24 2019

independent investigators at all academic levels (or equivalent)

• supports research that evaluates orthotic and/or prosthetic devices using patient-centric outcomes relevant to service members and veterans with limb loss and/or limb impairment
• proposed projects should be designed to provide outcomes data regarding orthotic and/or prosthetic devices and must include the anticipated effect on patient care metrics.
• multidisciplinary collaboration among academia, industry, the dod, the department of veterans affairs (va), and other federal government agencies is highly encouraged.
• applications submitted to the fy19 oporp cra must address one or more of the fy19 oporp focus areas.
• animal studies are not allowed.
• clinical trials are not allowed.
• the fy19 cra offers two funding levels:

funding level 1:

• ·       maximum funding of $350,000 for total costs (direct costs plus indirect costs)
• ·       maximum period of performance is 2 years

funding level 2:

• ·       maximum funding of $1,000,000 for total costs (direct costs plus indirect costs)
• ·       maximum period of performance is 4 years

clinical trial award – letter of intent due july 24, 2019

independent investigators at all academic levels (or equivalent)

• supports rapid implementation of clinical trials with the potential to make significant impacts on improving the health and well-being of service members, veterans, and other individuals living with limb deficit.
• supports clinical trials that evaluate orthotic and/or prosthetic devices using patient-centric outcomes.
• proposed projects should be designed to provide outcomes data regarding orthotic and/or prosthetic devices and must include the anticipated effect on patient care metrics.
• multidisciplinary collaboration among academia, industry, the military services, the va, and other federal government agencies is highly encouraged.
• applications submitted to the fy19 oporp cta must address one or more of the fy19 oporp focus areas.
• preclinical research is not allowed.

the fy19 cta offers two funding levels:

funding level 1:

• ·       maximum funding of $350,000 for total costs (direct costs plus indirect costs)
• ·       maximum period of performance is 2 years

funding level 2:

• ·       maximum funding of $2,000,000 for total costs (direct costs plus indirect costs)
• ·       maximum period of performance is 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrmc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the oporp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org

solicitation number: nnh18ztt001n-pt

release date: june 7, 2019

pre-proposal conference: june 25, 2019

step 1 proposals due: july 5, 2019

step 2 proposals due: september 26, 2019

research opportunities in space biology (rosbio) – 2018 “appendix c:  development of microgravity food production: plant watering, volume management, and novel plant research on the international space station”nnh18ztt001n-pt

this space biology appendix to rosbio-2018 represents a collaboration between nasa’s space life and physical science research and applications division (slpsrad) and nasa’s advanced exploration systems (aes). the goal of this collaboration is to solicit research and development (r&d) projects that will lead to the development of a more reliable water and nutrient delivery approach/concept for growing edible pick-and-eat plants for multiple generations in microgravity, that will eventually lead to new hardware.

through this solicitation, nasa seeks proposals for the integrated research and development of:

1) edible plant water and nutrient delivery systems for microgravity spaceflight that will provide sufficiently uniform wetting of the roots, avoid the release of free water, and maintain sufficient aeration and oxygen.

2) edible plant spacing systems that will optimize the use of plant-growing volume in space. 

nasa anticipates accomplishing its goal of procuring the development of a reliable space-ready plant water and nutrient delivery system in three distinct phases. phase-a involves key components and experiments, phase-b includes prototype development and system investigations, and phase-c involves demonstration on the iss.

this appendix is requesting phase-a proposals only for plant water and nutrient delivery systems, and/or plant spacing systems that can be used in a nasa furnished plant chamber, and may be scaled up to the size of a full rack on the iss or future spacecraft. key components for the design should be validated through modeling or performance testing.  preliminary scientific investigations and experiments to validate the system’s successful operation and ability to support future research studies should be included as appropriate. 

a virtual pre-proposal conference is scheduled for june 25^th 2019, and more details will be posted shortly alongside this solicitation on nspires. 

appendix c, which was released on june 7, 2019 can be found at https://tinyurl.com/nnh18ztt001n-pt by opening the nasa research opportunities homepage at http://nspires.nasaprs.com/ and then linking through the menu listings "solicitations" to "open solicitations."  step-1 (pre) proposals will be due july 5, 2019 at 5 pm eastern time, and invited step-2 full-length proposals will be due september 26, 2019 at 5 pm eastern time. proposals must be submitted electronically by an authorized official of the proposing organization. proposers may use either nspires (http://nspires.nasaprs.com/) or grants.gov (http://www.grants.gov) for step-1 proposal submission.  please see the solicitation for instructions regarding the submission of step-2 proposals.

all categories of u.s. institutions are eligible to submit proposals in response to this appendix. principal investigators (pis) and collaborators may be from universities, federal government laboratories, the private sector, state and local government laboratories and other countries with the exception of china.

this appendix will be a broad agency announcement as specified in far 6.102 (d)(2). all awards resulting from selections of proposals to this appendix will be grants or cooperative agreements.